Protara Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TARA Nasdaq 2830 www.protaratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protara Therapeutics, Inc.

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - Jan 12th, 2026 5:00 am
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - Jan 7th, 2026 6:00 am
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 7th, 2026 6:00 am
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - Jan 5th, 2026 6:00 am
Protara Announces Closing of $75 Million Public Offering - Dec 8th, 2025 2:05 pm
Protara Announces Pricing of $75 Million Public Offering - Dec 4th, 2025 8:03 pm
Protara Announces Proposed Public Offering - Dec 4th, 2025 2:15 pm
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - Dec 3rd, 2025 6:00 am
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Dec 1st, 2025 2:15 pm
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30% - Nov 24th, 2025 6:17 am
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - Nov 19th, 2025 6:00 am
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 - Nov 18th, 2025 2:30 pm
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology - Nov 17th, 2025 6:00 am
Protara Therapeutics: Q3 Earnings Snapshot - Nov 10th, 2025 6:06 am
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 10th, 2025 6:00 am
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace - Nov 4th, 2025 2:05 pm
Protara Therapeutics, Inc. (NASDAQ:TARA) is favoured by institutional owners who hold 74% of the company - Oct 28th, 2025 6:57 am
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 1st, 2025 2:03 pm
A Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI Index - Sep 24th, 2025 5:27 am
What Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For Shareholders - Sep 22nd, 2025 4:36 am